Skip to main content

Elevit Film Coated Tablet, Bayer Australia Ltd, CON-186

Product name
Elevit Film Coated Tablet
Sponsor name
Bayer Australia Ltd
Consent start
Consent no.
CON-186
Standard
Sections 11(a), 11(b) and 11(c) of the Therapeutic Goods Order No. 78 - Standard for Tablets and Capsules (TGO78)
Non-compliance with standard
Section 11(a) of the (TGO 78) requires that a registered tablet or capsule without an individual British Pharmacopoeia (BP) monograph must comply with the test for Uniformity of Dosage Units of the BP, in the general monographs 'Tablets' or 'Capsules', respectively. With respect to a registered tablet or capsule without an individual BP monograph, section 11(b), TGO 78 requires that the average content of each active ingredient in a pooled sample of not fewer than 20 tablets or capsules must be not less than 92.5% and not more than 107.5% of the stated content of that active ingredient. With respect to section 11(c), TGO 78 requires that a registered tablet or capsule without an individual BP monograph must comply with a suitable test for dissolution that demonstrates the appropriate release of each active ingredient for which the BP or United States Pharmacopeia-National Formulary (USP-NF) includes an individual monograph for a tablet or capsule and requires a test for dissolution.
Conditions imposed
    1. The goods are not required to comply with TGO 78 section 11(a) but must comply with the requirements of the British Pharmacopoeia Appendix XII C Uniformity of Weight (Mass).2. The goods are not required to comply with TGO 78 section 11(b) but the average content of each active ingredient in the goods must comply with the relevant acceptance criteria included in Attachment 2.3. The goods are not required to comply with TGO 78 section 11(c) but must comply with the dissolution requirements of the United States Pharmacopeia-National Formulary, Dietary Supplement Chapter 2040 'Disintegration and Dissolution of Dietary Supplements' for riboflavine (Vitamin B2) and iron as set out in Attachment 2.  
Therapeutic product type
Over-the-counter medicines

Help us improve the Therapeutic Goods Administration site